SNPMiner Trials by Shray Alag

SNPMiner SNPMiner Trials (Home Page)

Report for Clinical Trial NCT02095782

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Intercalated Combination of Chemotherapy and Erlotinib in 1st Line Setting for Patients Advanced Stage Non-small-cell Lung Cancer With Low Abundant Activating EGFR Mutation(INNOVATE)

This is a single arm phase II clinical trial, which aims to evaluate the effectiveness of intercalated combination of doublet chemotherapy of paclitaxel plus carboplatin and erlotinib on patients with advanced stage non-small-cell lung cancer with low abundant activating EGFR mutation.

NCT02095782 Non-small-cell Lung Cancer
MeSH:Lung Neoplasms Carcinoma, Non-Small-Cell Lung
HPO:Neoplasm of the lung Non-small cell lung carcinoma

1 Interventions

Name: Intercalated combination of chemotherapy and erlotinib

Description: Primary therapy stage: Paclitaxel Patients receive six cycles of Paclitaxel (175 mg/m² on days 1 of a 4 week cycle, intravenously) plus carboplatin (AUC=5, intravenously on day 1 of a 4 week cycle, intravenously) with sequential erlotinib (150 mg/day) on days 8-21 of each cycle. Maintenance therapy stage: Patients, who complete 6 cycles of therapy without progression or intolerable toxicity, receive erlotinib (150 mg/day) as maintenance therapy until progression, intolerable toxicity or death.
Type: Drug
Group Labels: 1

chemotherapy and erlotinib

Primary Outcomes

Description: From start of anti-cancer therapy untill progression or death

Measure: Progression free survival defined by imagery methods

Time: 8 weeks

Secondary Outcomes

Description: From start of anti-cancer therapy till progression of death

Measure: Toxicities related to anti-cancer therapy

Time: 8 weeks

Purpose: Treatment

Allocation: N/A

Single Group Assignment

There is one SNP


1 L858R

Low abundant activating EGFR mutation: EGFR exon 19 deletion or exon 21 L858R, which are positive by real-time PCR methods and negative by standard sequencing methods. --- L858R ---

HPO Nodes